Skip to Content

Join the 'Alirocumab' group to help and get support from people like you.

Alirocumab News

Are There Alternatives to Statins?

Posted 27 Sep 2016 by Drugs.com

TUESDAY, Sept. 27, 2016 – Statins are the go-to therapy for lowering "bad" LDL cholesterol, but other treatments also can effectively reduce risk of future heart problems, a new evidence review reports. These alternative therapies – including a heart-healthy diet, other cholesterol-lowering medications, and even intestinal bypass surgery – seem to confer the same level of heart health protection as statins when cholesterol levels decrease, according to the findings. Nonstatin therapies reduced the risk of heart problems by 25 percent for each 1 millimole per liter (mmol/L) decrease in LDL cholesterol levels. That's very similar to the 23 percent reduction per 1 mmol/L decrease seen with statins like atorvastatin (Lipitor) and simvastatin (Zocor), the researchers said. What's more, the benefits of these therapies stack up if more than one proves effective at lowering a person's ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Welchol, Zocor, Cholestyramine, Lovastatin, Zetia, Vytorin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Gastric Bypass Surgery, Questran, Pravachol, Livalo, High Cholesterol - Familial Homozygous

Negative News on Statins Tied to Dropped Prescriptions

Posted 2 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 2, 2015 – News reports on the downsides of statins may push some people to stop taking the cholesterol-lowering drugs, a new study hints. The findings, published Dec. 2 in the European Heart Journal, cannot prove that media stories drive statin users to give up their prescriptions. Instead, Danish researchers found a broad correlation between "negative" media coverage and people's odds of quitting a statin within six months of their first prescription. But even without a clear cause-and-effect connection, experts said it's reasonable to assume that media stories had an influence over some statin users in the study. It rings true to Dr. Thomas Whayne Jr., of the Gill Heart Institute at the University of Kentucky. "I've seen this happen a lot," said Whayne, who was not involved in the study. "News stories come out, and you have patients saying, 'I'm not going to take ... Read more

Related support groups: Diabetes, Type 2, Muscle Pain, Heart Disease, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Zetia, Pre-Diabetes, Vytorin, Rosuvastatin, Hypertriglyceridemia, Pravachol, Livalo, Red Yeast Rice, Cardiovascular Risk Reduction

Heart Disease Doesn't Take a Holiday

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – People with heart disease should take a number of precautions if they travel over the Thanksgiving holiday, an expert suggests. The first step is to be as well-prepared on your trip as you are at home, said Dr. Winston Gandy Jr., a cardiologist at Piedmont Heart Institute in Atlanta. "Make sure when you travel that you have your medicine," Gandy said in an American Heart Association news release. Some people carry a copy of their original prescriptions in case they lose their medications, but having a list of your medications and your cardiologist's phone number should be sufficient. It's also a good idea to tell your cardiologist where you'll be. "Chances are your cardiologist is going to know someone there, either personally or by reputation," who can provide you with help if needed, Gandy said. Research medical facilities at your destination, and know what ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Niacin, Zocor, Niaspan, Azor, Lovastatin, Benicar HCT, Exforge, Diovan HCT, Hyzaar, Rosuvastatin, Lotrel, Avalide, Pravachol, Hydrochlorothiazide/Lisinopril, Livalo

FDA OKs Praluent - First of New Class of Cholesterol Drugs

Posted 27 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – The U.S. Food and Drug Administration on Friday approved Praluent, the first of a powerful new class of injected, cholesterol-lowering drugs that experts believe could change cardiovascular care. Praluent (alirocumab) sharply cuts levels of LDL ("bad") cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors, the FDA explained in a news release. The drug is only approved for patients with heart disease and a history of heart attack or stroke "who require additional lowering of LDL cholesterol" in addition to taking a statin drug and adopting a healthy diet, the agency said. It is also for use by patients with a condition called heterozygous familial hypercholesterolemia (HeFH), an inherited illness that causes people to have high levels of LDL in the blood. "Praluent provides another treatment option for patients with HeFH or with ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Praluent Approved to Treat High Cholesterol

Posted 27 Jul 2015 by Drugs.com

MONDAY, July 27, 2015 – Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration to treat people with inherited high cholesterol (heterozygous familial hypercholesterolemia) or people at risk of heart attack or stroke from high cholesterol derived from foods or produced by the liver. The drug is sanctioned for people who do not benefit enough from improved diet and the use of cholesterol-lowering statins. Low-density lipoprotein (LDL, the so-called "bad cholesterol") is linked to cardiovascular disease. Heart disease is the leading cause of death among American men and women, killing some 610,000 people every year, the FDA said in a news release. Praluent is the first-approved drug in a new class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The drug is an antibody that inhibits the PCSK9 protein, which allows ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol

Posted 27 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. HeFH is an inherited condition that causes high levels of low-density lipoprotein (LDL) cholesterol. A high level of LDL cholesterol (known as “bad” cholesterol) in the blood is linked to cardiovascular disease. Heart disease is the number one cause of death for Americans, both men and women. According to the Centers for Disease Con ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol

Related Drug Support Groups

Praluent

Alirocumab Patient Information at Drugs.com